Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, Genazzani A R
Department of Procreative Medicine, University of Pisa, Italy.
Anticancer Res. 1998 Sep-Oct;18(5B):3763-5.
Serum anti-p53 antibodies have been detected in different human malignancies, including ovarian carcinoma. In the present investigation these autoantibodies were retrospectively measured with a new ELISA (Immunotech, Marseilles, France) before first surgery and subsequently at different times during the course of disease from 40 patients with advanced ovarian carcinoma. Anti-p53 antibodies were preoperatively found in 15 (37.5%) patients. With regard to the follow-up of these 15 patients, anti-p53 antibodies were detected in 87.8% of the 41 samples drawn when there was clinical evidence of disease compared to 57.1% of the 14 samples collected when there was no clinical evidence of tumor (p = 0.037). As for the 25 patients whose serum originally scored negative, the autoantibodies were found only in 1.8% of the 113 samples obtained during the follow-up, independently of the status of disease. In conclusion, anti-p53 antibodies are often detected in serum from patients with advanced ovarian carcinoma. However, the serial measurement of these autoantibodies does not seem to give useful clinical information for the follow-up of these patients.
在包括卵巢癌在内的不同人类恶性肿瘤中均检测到血清抗p53抗体。在本研究中，采用一种新的酶联免疫吸附测定法（Immunotech，法国马赛）对40例晚期卵巢癌患者首次手术前以及疾病过程中不同时间的这些自身抗体进行了回顾性检测。术前在15例（37.5%）患者中发现了抗p53抗体。关于这15例患者的随访情况，在有疾病临床证据时采集的41份样本中，87.8%检测到抗p53抗体，而在无肿瘤临床证据时采集的14份样本中，这一比例为57.1%（p = 0.037）。对于最初血清检测为阴性的25例患者，在随访期间获得的113份样本中，仅1.8%检测到自身抗体，与疾病状态无关。总之，晚期卵巢癌患者血清中常检测到抗p53抗体。然而，对这些自身抗体进行系列检测似乎并不能为这些患者的随访提供有用的临床信息。
